Merck’s licensing deal with SciBrunch further cements the company’s focus on building next waves of precision oncology programs through external innovation sourcing. The deal covers development, manufacturing, and commercialization rights for SPR2015, a KRAS G12D (ON) inhibitor in molecular-glue format. While SciBrunch’s program remains preclinical, the agreement structure ties value to near-to-mid-term development and future commercialization milestones, with a significant upfront payment signaling commitment to accelerate work toward first-in-human studies. Taken with Merck’s other external innovation moves, the SciBrunch partnership emphasizes speed-to-optionality as Merck navigates crowded oncology landscapes.